SIGLEC6

Across TCGA pan-cancer cohorts, SIGLEC6 RNA differs between tumor and matched normal tissue in 8 of 18 cancer types tested, making tumor–normal expression one of SIGLEC6’s most consistent transcriptional readouts.

The strongest signal is observed in lung adenocarcinoma (LUAD), where SIGLEC6 RNA is repressed in tumor relative to normal tissue. In most cancer types SIGLEC6 is over-expressed in tumor, although a few such as LUAD and COAD show the opposite, repressed pattern.

LUAD, THCA, and COAD are the cancer types where SIGLEC6 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SIGLEC6 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LUAD	Female	II,III,IV	−1.281	<.001	11	view →
THCA	All	II,III,IV	+1.628	<.001	10	view →
COAD	Female	II,III,IV	−0.901	<.001	10	view →
LUSC	Female	All	−1.516	<.001	6	view →
BLCA	Male	III,IV	−1.148	.005	6	view →
KIRC	All	All	+0.303	<.001	5	view →
READ	All	All	−0.802	.004	3	view →
UCEC	All	All	−0.584	<.001	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 8 strongest of 8 lineages.

SIGLEC6–LUAD

Open the LUAD breakdown →